Description
Skyrizi (Risankizumab) is a prescription medication used to treat moderate to severe plaque psoriasis in adult patients. It comes in the form of an injection and works by blocking a protein called interleukin-23 (IL-23), which is involved in the immune response that causes inflammation in the body.
Uses:
Skyrizi is used to treat adult patients with moderate to severe plaque psoriasis. Psoriasis is a chronic autoimmune skin disorder that causes thick, scaly patches on the skin. These patches are often itchy and painful and can cause significant discomfort and embarrassment for patients.
Storage conditions:
Skyrizi should be stored in the refrigerator at a temperature between 2°C and 8°C (36°F and 46°F). Do not freeze this medication. It should be kept out of reach of children and pets.
Mechanism of action:
Skyrizi works by blocking IL-23, which is involved in the immune response that causes inflammation in the body. By blocking IL-23, Skyrizi reduces the inflammation that leads to psoriasis symptoms.
HOW TO USE:
Skyrizi is administered as a subcutaneous injection by a healthcare provider. The usual dose is 150 mg once every 12 weeks after the starting dose at week 0 and week 4. Patients should be monitored for side effects during and after the injection.
Precautions:
Skyrizi should not be used in patients with a known hypersensitivity to risankizumab or any of its components. Patients should be monitored for signs of allergic reactions, such as itching, hives, or difficulty breathing. Patients should also be monitored for infections and should avoid contact with individuals who have active infections.
Drug interactions:
Skyrizi may interact with other medications, so patients should inform their doctor or pharmacist if they are taking any other medications, including over-the-counter products, herbal supplements, and vitamins. Specific drug interactions with Skyrizi are not yet known.
Contraindications:
Skyrizi is contraindicated in patients with a history of hypersensitivity to risankizumab, and it should not be used in patients with active tuberculosis or other severe infections.
Overdose:
In the event of an overdose of Skyrizi, patients should seek immediate medical attention. There is limited information on the effects of an overdose of risankizumab.
Adverse reactions:
Common adverse reactions associated with Skyrizi include upper respiratory infections, headache, fatigue, injection site reactions, and abdominal pain. These side effects are usually mild to moderate and resolve on their own. However, patients should seek medical attention if these side effects persist or worsen.
In summary, Skyrizi is an effective medication in the treatment of adult patients with moderate to severe plaque psoriasis. It blocks the protein IL-23, reducing inflammation that leads to psoriasis symptoms. It should be administered by a healthcare provider, and patients should be monitored for potential allergic reactions and infections. Patients should be aware of potential side effects and should seek medical attention if necessary.
Reviews
There are no reviews yet.